Testing a new immunotherapy for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new immunotherapy drug, GIGA-564, for people with advanced solid tumors that have not responded to or have returned after standard treatments. The goal is to see if the drug is safe and effective, and to find the best dose.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced cancer that has spread (metastatic) and has not responded to standard treatments or has come back after at least one treatment.
- You have at least one tumor that can be measured on a scan (like a CT or MRI).
- You are feeling well enough to do most of your daily activities (ECOG 0 or 1).
- Your blood counts and organ function (kidney, liver, heart) are within range as tested by your doctor.
- You have not had prior treatment with certain immune therapies (like ipilimumab, or drugs targeting CCR8, CD25, or TIGIT).
- You do not have an active autoimmune disease that required treatment in the last 2 years, or active untreated brain metastases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests a new antibody drug (GNC-039) that targets a specific feature found on some cancer cells. It is for adults with solid tumors that have come back or stopped responding to standard treatment, aiming to see safety and early signs of effectiveness.
This trial tests a new combination of two study drugs (GH55 and GH21) for people with advanced solid tumors that have certain genetic changes. The goal is to see if the combo is safe and can help shrink tumors or slow their growth.
This trial tests a new immunotherapy drug (called MEDI5752) for people with certain solid tumors that have a special immune feature called 'mature tertiary lymphoid structures.' The drug is designed to help your immune system fight the cancer more effectively. You may be able to join even if you haven't had immunotherapy before, or if you had it and it stopped working after a while.
This trial tests an experimental antibody drug called SIG001 for people with advanced solid tumors that haven't responded to standard treatments. It aims to see if the drug is safe and how well it works.
This trial tests a new drug called GB268, which is designed to help your immune system fight cancer. It is for people with advanced solid tumors that have not responded to standard treatments.
This Phase 1 trial tests a new drug called IUAb190708 designed to help your immune system fight advanced or recurrent solid cancers. The study will evaluate its safety, how your body handles it, and whether it works against your tumor.
Hear when a new Advanced or Metastatic Solid Tumor Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.